Leeds, United Kingdom
VIDEREGEN LIMITED, founded in 2011, is a United Kingdom-based company at the forefront of regenerative medicine. Emphasizing their slogan, "Bringing tissue repair to life," Videregen is developing an innovative immunotherapeutic platform anchored in advanced stem cell science. Their primary focus is on engineering a bioengineered thymus to potentially treat immunodeficiencies, autoimmune diseases, and enhance transplant tolerance—areas significantly impacted by thymus dysfunction.
Positioned within the Biotechnology, Health Care, Medical Devices, and Pharmaceutical industries, Videregen stands to address critical health challenges, particularly related to immune and age-related disorders.
The company's ongoing development is backed by a strong financial foundation, with a noteworthy £3.10M Series A investment completed on 24 October 2014. Investors such as The North West Fund, Newable Private Investing, Innovate UK, and Deepbridge Capital have shown confidence in Videregen's potential to revolutionize regenerative medicine.
